Tenofovir alafenamide (TAF, Vemlidy) costs USD 1,400+ per month in the US. In China, the same molecule from licensed hospital pharmacies costs USD 15–30. Here is the full clinical context.
Chronic hepatitis B affects approximately 296 million people globally per WHO estimates. Modern nucleos(t)ide analogues — entecavir, tenofovir disoproxil (TDF), and tenofovir alafenamide (TAF) — suppress HBV DNA to undetectable in over 95% of treatment-naive patients, dramatically reducing risk of cirrhosis and hepatocellular carcinoma. The catch in Western markets has always been price — TAF (Vemlidy) lists in the US around USD 1,400–1,800 per month, even though manufacturing cost is a small fraction of that.
The Drug, in One Paragraph
Chronic hepatitis B affects approximately 296 million people globally per WHO estimates. Modern nucleos(t)ide analogues — entecavir, tenofovir disoproxil (TDF), and tenofovir alafenamide (TAF) — suppress HBV DNA to undetectable in over 95% of treatment-naive patients, dramatically reducing risk of cirrhosis and hepatocellular carcinoma. The catch in Western markets has always been price — TAF (Vemlidy) lists in the US around USD 1,400–1,800 per month, even though manufacturing cost is a small fraction of that.
The China Picture
In China, both TDF (generic) and TAF are widely available at Class A international departments at substantially lower cost:
- Generic tenofovir disoproxil (TDF): USD 5–15 per month
- Tenofovir alafenamide (TAF): USD 15–30 per month
- Entecavir generic: USD 8–20 per month
These are licensed pharmaceutical-grade products from regulated supply, not gray-market sources.
Should You Get Tested?
Most international guidelines now recommend at least one-time HBV testing for adults. Higher-risk populations — adults born in HBV-endemic regions (China, SE Asia, Africa, parts of E Europe), adults with parents born in such regions, household contacts of HBV-positive individuals — should be tested without delay. Take our free HBV risk screener for a structured 3-minute risk stratification.
The Workup Standard at Class A Centres
If positive on screening, comprehensive evaluation typically includes:
- HBsAg + anti-HBs + anti-HBc (initial), HBeAg + anti-HBe, HBV DNA quantitation
- ALT, AST, GGT, complete metabolic panel, alpha-fetoprotein
- Abdominal ultrasound and FibroScan transient elastography for fibrosis staging
- Hepatology consultation with treatment recommendation
This block is typically USD 200–340 all-in at a Class A international department.
Why the Cost Gap Exists
China's centralised pharmaceutical procurement, generic competition, and patent landscape combine to make antivirals affordable. The TAF molecule has long been on China's National Reimbursement Drug List, with negotiated pricing for the public system that flows through to international department pricing.
What to Do Next
If you haven't been screened in the last 5 years, get tested. If you're already diagnosed and on imported brand antivirals, it's worth comparing what a 6-month or 12-month supply costs through a Class A international department. See our tenofovir China page for current pricing and partner hospitals.
Sources: AASLD 2018 chronic hepatitis B guidance; WHO global hepatitis report 2024; Chinese National Reimbursement Drug List 2025; partner-hospital pricing data 2026.